Analytical Data
-
基因名
BTN3A1
- Application
-
别名
BTN3A1；BTF5；Butyrophilin subfamily 3 member A1
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
O00481
-
表达区间
31-254aa
-
氨基酸序列
FSVLGPSGPI LAMVGEDADL PCHLFPTMSA ETMELKWVSS SLRQVVNVYA DGKEVEDRQS APYRGRTSIL RDGITAGKAA LRIHNVTASD SGKYLCYFQD GDFYEKALVE LKVAALGSDL HVDVKGYKDG GIHLECRSTG WYPQPQIQWS NNKGENIPTV EAPVVADGVG LYAVAASVIM RGSSGEGVSC TIRSSLLGLE KTASISIADP FFRSAQRWIA ALAG
-
分子量
53 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
BTN3A1, a member of the butyrophilin family, plays a critical role in the immune response, particularly in the context of presenting antigens to T cells. It is involved in the recognition and modulation of various immune pathways, influencing both innate and adaptive immunity. Recent studies have highlighted its importance in the activation of γδ T cells, which are pivotal in the early response to infections and tumors. BTN3A1 interacts with phosphoantigens, leading to the activation of these unconventional T cells, thus making it a potential target for immunotherapy. Researchers have been exploring recombinant BTN3A1 proteins for their utility in studying T cell activation mechanisms and developing novel therapeutic strategies. The recombinant versions of BTN3A1 can facilitate precise investigations into its structural and functional properties, aiding in the understanding of its role in immune regulation. Additionally, these studies might provide insights into manipulating γδ T cell responses in cancer and infectious diseases, highlighting BTN3A1 as a promising candidate for the development of targeted immunotherapies.
